Market Overview

Canaccord Starts Penumbra At Buy, Sees 'Stroke Of Genius'

  • The share price of Penumbra, Inc. (NYSE: PEN) has declined 5.23 percent over the past month, reaching a low of $38.90 on Monday.
  • Canaccord Genuity’s Jason Mills has initiated coverage of the company with a Buy rating and price target of $48.
  • Mills believes that Penumbra is very well positioned to benefit from the development and growth of the global interventional stroke market over the next several years.

According to the Canaccord Genuity report, “PEN possesses a rare combination of size, scale, compelling target markets, broad/differentiated product portfolio, and strong share positions for a small-cap med-tech company.”

Analyst Jason Mills also explained that the company has a robust margin profile and a “penchant” for profitability, and is expected to return to profitability soon, all of which differentiate Penumbra from its small cap med-tech peers.

In addition, the company has a strong, deep, tenured and successful leadership team. Since Penumbra’s inception in 2004, the management has “built a unique culture among its teammates that eschews internal politics, respects but challenges dogma, and prioritizes constant, expeditious innovation, both iterative and revolutionary,” Mills stated.

Mills also expects large cap med-tech companies to see Penumbra as an attractive acquisition target, although the company is expected to succeed as a stand-alone entity in the long term.

The company’s largest business, acute ischemic stroke, grew 46 percent in 2015 and 50 percent in the first half of 2015, following clinical trials that demonstrated the efficacy of Penumbra’s mechanical thrombectomy intervention.

Latest Ratings for PEN

May 2019UpgradesNeutralOverweight
Nov 2018MaintainsMarket PerformMarket Perform
Oct 2018Initiates Coverage OnOutperform

View More Analyst Ratings for PEN
View the Latest Analyst Ratings

Posted-In: Canaccord Genuity Jason MillsAnalyst Color Initiation Analyst Ratings


Related Articles (PEN)

View Comments and Join the Discussion!

Latest Ratings

NVROOppenheimerInitiates Coverage On
SWAVOppenheimerInitiates Coverage On
LEVIMacquarieInitiates Coverage On
KTBMacquarieInitiates Coverage On
IFCTD SecuritiesMaintains145.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Leerink: Time To Buy Nabriva Therapeutics' 'Unique Differentiation'

Zosano Pharma Announces Positive Phase 2 Results for Its ZP-Glucagon Patch Program for Treatment of Severe Hypoglycemia